HOME ·

SKB BIO

SKB BIO (06990.HK): Positive Phase II Interim Results for SKB378/WIN378 in Asthma; Phase III Initiated
Tags：
SKB BIO06990.HKR&D Progress
2026-09-08
SKB BIO(06990.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 388.01 million, turned profitable from a loss YoY
Tags：
SKB BIO06990.HKturned profitable from loss
2026-08-18
SKB BIO (06990.HK): NMPA Accepts sNDA for Core Product Sac-TMT in First-Line TNBC Treatment
Tags：
SKB BIO06990.HKPriority Review
2026-07-30
SKB BIO (06990.HK) plans to issue in total 5.84 million shares by placement, with estimated net proceeds of HKD 2.72 billion
Tags：
SKB BIO06990.HKNewTimeSpace
2026-07-08